FDA Blocks Compounding of Obesity Drug Ingredients
The U.S. Food and Drug Administration proposed Friday to exclude the active ingredients in blockbuster obesity and diabetes drugs from a list of substances eligible for large-scale compounding. The decision targets semaglutide—used in Novo Nordisk's Wegovy and Ozempic—and tirzepatide—used in Eli Lilly's Mounjaro and Zepbound.
“There is no clinical need for large compounding facilities to produce these medications in bulk,” an FDA spokesperson said. The move is a clear victory for Novo Nordisk and Eli Lilly, which have faced growing competition from cheaper compounded versions amid surging demand for weight-loss treatments.
The agency determined that these compounders no longer meet legal requirements to market their products. This decision will reshape consumer access, as compounded versions have been a key alternative during shortages over the past few years.
FDA Names Katherine Szarama as Acting CBER Director
In a separate development, the FDA named Katherine Szarama as acting director of the Center for Biologics Evaluation and Research (CBER), which regulates vaccines, gene therapies, and blood products. She replaces Vinay Prasad, who left the agency Thursday after a tumultuous tenure marked by controversial decisions on rare disease drugs and vaccines.
“Dr. Szarama brings valuable experience from her role as deputy director,” said FDA Commissioner Marty Makary. It remains unclear if she will serve permanently. Previously, ophthalmologist and biopharma executive Houman Hemmati was considered a top candidate for the position.
Background
The compounding controversy has escalated as demand for GLP-1 agonists like semaglutide and tirzepatide soared. Compounders argued they filled critical gaps during shortages, but brand-name manufacturers pushed back, citing safety, efficacy, and patent concerns. The FDA's proposal follows months of debate and legal pressure from Novo Nordisk and Eli Lilly.
At CBER, Prasad’s exit ends a period of instability. His decisions—including rare disease drug approvals and vaccine mandate stances—drew criticism from both industry and public health advocates. Szarama joined the FDA late last year to serve as his deputy.
What This Means
For patients, the compounding restriction may limit access to cheaper versions of obesity drugs, potentially increasing costs. However, brand-name supply is expected to improve as shortages ease. For investors, the decision reinforces patent protection for Novo Nordisk and Eli Lilly, boosting their market dominance.
The leadership change at CBER signals a potential shift in regulatory approach for biologics. Szarama’s tenure will be closely watched as the FDA navigates gene therapy approvals, vaccine policy, and ongoing oversight of the blood supply.
This story is developing. Check back for updates.
See Background and What This Means for more context.